Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 2.29 Million CAD | 31.75% |
| 2023 | 1.58 Million CAD | 39.02% |
| 2022 | 1.13 Million CAD | -42.73% |
| 2021 | 1.98 Million CAD | 63.1% |
| 2020 | 1.21 Million CAD | 196.26% |
| 2019 | -1.26 Million CAD | -7324.29% |
| 2018 | -17.06 Thousand CAD | -1789.7% |
| 2017 | -903.00 CAD | -140.28% |
| 2016 | 2242.00 CAD | 125.81% |
| 2015 | -8687.00 CAD | -13473.44% |
| 2014 | -64.00 CAD | 99.75% |
| 2013 | -25.94 Thousand CAD | 86.06% |
| 2012 | -186.12 Thousand CAD | 23.05% |
| 2011 | -241.88 Thousand CAD | -209.34% |
| 2010 | -78.19 Thousand CAD | 31.74% |
| 2009 | -114.55 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | 2.29 Million CAD | -19.28% |
| 2024 FY | 2.29 Million CAD | 44.78% |
| 2024 Q3 | 2.84 Million CAD | 20.31% |
| 2024 Q1 | 1.73 Million CAD | 9.25% |
| 2024 Q2 | 2.36 Million CAD | 36.45% |
| 2023 FY | 1.58 Million CAD | 39.02% |
| 2023 Q4 | 1.58 Million CAD | 0.8% |
| 2023 Q3 | 1.57 Million CAD | 8.16% |
| 2023 Q2 | 1.45 Million CAD | 32.83% |
| 2023 Q1 | 1.09 Million CAD | -4.0% |
| 2022 Q3 | 1.13 Million CAD | 43.78% |
| 2022 Q4 | 1.13 Million CAD | 0.67% |
| 2022 FY | 1.13 Million CAD | -42.73% |
| 2022 Q1 | 842.02 Thousand CAD | -57.66% |
| 2022 Q2 | 786.96 Thousand CAD | -6.54% |
| 2021 Q2 | 1.36 Million CAD | 28.1% |
| 2021 FY | 1.98 Million CAD | 63.1% |
| 2021 Q4 | 1.98 Million CAD | 31.43% |
| 2021 Q3 | 1.51 Million CAD | 10.77% |
| 2021 Q1 | 1.06 Million CAD | -12.55% |
| 2020 Q3 | 1.26 Million CAD | 463.59% |
| 2020 Q1 | -1.12 Million CAD | 10.92% |
| 2020 Q2 | -347.38 Thousand CAD | 69.22% |
| 2020 Q4 | 1.21 Million CAD | -3.45% |
| 2020 FY | 1.21 Million CAD | 196.26% |
| 2019 FY | -1.26 Million CAD | -7324.29% |
| 2019 Q1 | -668.66 Thousand CAD | -104.94% |
| 2019 Q3 | -4.36 Million CAD | 27.68% |
| 2019 Q4 | -1.26 Million CAD | 70.98% |
| 2019 Q2 | -6.03 Million CAD | -802.8% |
| 2018 Q4 | -326.26 Thousand CAD | -23645.78% |
| 2018 Q3 | -1374.00 CAD | 91.95% |
| 2018 Q2 | -17.06 Thousand CAD | -1094.12% |
| 2018 Q1 | -1429.00 CAD | 75.23% |
| 2018 FY | -17.06 Thousand CAD | -1789.7% |
| 2017 Q3 | -31.11 Thousand CAD | -3345.85% |
| 2017 Q4 | -5768.00 CAD | 81.46% |
| 2017 FY | -903.00 CAD | -140.28% |
| 2017 Q1 | 3479.00 CAD | 21.39% |
| 2017 Q2 | -903.00 CAD | -125.96% |
| 2016 Q1 | -357.00 CAD | -110.4% |
| 2016 FY | 2242.00 CAD | 125.81% |
| 2016 Q3 | -732.00 CAD | -132.65% |
| 2016 Q2 | 2242.00 CAD | 728.01% |
| 2016 Q4 | 2866.00 CAD | 491.53% |
| 2015 FY | -8687.00 CAD | -13473.44% |
| 2015 Q1 | - CAD | 100.0% |
| 2015 Q2 | -8687.00 CAD | 0.0% |
| 2015 Q4 | 3433.00 CAD | 155.6% |
| 2015 Q3 | -6174.00 CAD | 28.93% |
| 2014 Q4 | -55.00 CAD | 68.39% |
| 2014 FY | -64.00 CAD | 99.75% |
| 2014 Q2 | -64.00 CAD | -8.47% |
| 2014 Q1 | -59.00 CAD | 63.58% |
| 2014 Q3 | -174.00 CAD | -171.88% |
| 2013 Q2 | -25.94 Thousand CAD | 2.36% |
| 2013 Q4 | -162.00 CAD | 97.86% |
| 2013 FY | -25.94 Thousand CAD | 86.06% |
| 2013 Q1 | -26.57 Thousand CAD | 66.2% |
| 2013 Q3 | -7585.00 CAD | 70.76% |
| 2012 FY | -186.12 Thousand CAD | 23.05% |
| 2012 Q2 | -186.12 Thousand CAD | 3.37% |
| 2012 Q1 | -192.62 Thousand CAD | 5.06% |
| 2012 Q3 | -130.16 Thousand CAD | 30.07% |
| 2012 Q4 | -78.59 Thousand CAD | 39.61% |
| 2011 Q3 | -235.35 Thousand CAD | 2.7% |
| 2011 Q1 | -251.55 Thousand CAD | 4.57% |
| 2011 Q2 | -241.88 Thousand CAD | 3.84% |
| 2011 Q4 | -202.89 Thousand CAD | 13.79% |
| 2011 FY | -241.88 Thousand CAD | -209.34% |
| 2010 FY | -78.19 Thousand CAD | 31.74% |
| 2010 Q3 | -45.86 Thousand CAD | 41.35% |
| 2010 Q4 | -263.58 Thousand CAD | -474.72% |
| 2010 Q2 | -78.19 Thousand CAD | 0.0% |
| 2009 FY | -114.55 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | -20.733% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 85.456% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -470.516% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.327% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -2.247% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.643% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 136.365% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -147.266% |
| Marizyme, Inc. | 18.56 Million USD | 87.654% |
| Genus plc | 190.6 Million USD | 98.797% |
| Pharming Group N.V. | 109.8 Million USD | 97.912% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -166.508% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -88.865% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -237.149% |
| ContraFect Corporation | -6.02 Million USD | 138.045% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -98.421% |
| IMV Inc. | 7.67 Million USD | 70.111% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 58.33% |
| ONE Bio Corp. | 9.04 Million USD | 74.639% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 82.291% |
| Mesoblast Limited | 55.85 Million USD | 95.896% |
| MultiCell Technologies, Inc. | 90.04 USD | -2546116.126% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.497% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.216% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -268.372% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -127.506% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 44.327% |
| Biomind Labs Inc. | 711.4 Thousand USD | -222.267% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -14.666% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 82.098% |
| Skye Bioscience, Inc. | -5.72 Million USD | 140.071% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -537.35% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -2.54% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1539.877% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1602.785% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 59.411% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -11439.805% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 412.354% |
| EV Biologics, Inc. | 1.36 Million USD | -67.592% |
| Q BioMed Inc. | 4.06 Million USD | 43.532% |
| GB Sciences, Inc. | 1.74 Million USD | -31.208% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1347.423% |
| CSL Limited | 10.52 Billion USD | 99.978% |
| Agentix Corp. | 37.63 Thousand USD | -5992.352% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.213% |
| Enzolytics Inc. | 981.65 Thousand USD | -133.545% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 64.461% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 440.611% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -4.116% |
| argenx SE | -2.02 Billion USD | 100.113% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.722% |
| HST Global, Inc. | 96.79 Thousand USD | -2268.573% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.877% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1011.748% |
| Halberd Corporation | 144.72 Thousand USD | -1484.161% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 67.577% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 125.935% |
| Zenith Capital Corp. | 10.06 Thousand USD | -22680.336% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 15.358% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 3.915% |
| AVAX Technologies, Inc. | -5.9 Million USD | 138.837% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1293.609% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 12615.629% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1043.836% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | -5.24% |
| Helix BioMedix, Inc. | -2.57 Million USD | 189.206% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 88.693% |
| Kadimastem Ltd | -253.1 Thousand USD | 1005.806% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 48.734% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1039.164% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 175108.626% |
| LadRx Corporation | -2.03 Million USD | 212.578% |
| Cell Source, Inc. | 9.23 Million USD | 75.167% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 11333.894% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -260.946% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -260.946% |
| Affymax, Inc. | -5.59 Million USD | 140.961% |
| Mobile Lads Corp. | 484.23 Thousand USD | -373.453% |
| Itoco Inc. | 228.3 Thousand USD | -904.189% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1585.881% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 53.75% |
| International Stem Cell Corporation | 2.59 Million USD | 11.482% |
| CytoDyn Inc. | 20.26 Million USD | 88.685% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 354445.131% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 24835.961% |
| Qrons Inc. | 351.42 Thousand USD | -552.372% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 70.249% |
| SYBLEU INC | 473.71 Thousand USD | -383.966% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1018.441% |
| Rebus Holdings, Inc. | 305 Thousand USD | -651.676% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 48.562% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3573.294% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -5.122% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 33.238% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 73.195% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -196.737% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 283.409% |
| Neutra Corp. | 52.18 Thousand USD | -4293.073% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 192.11% |
| PureTech Health plc | -167.19 Million USD | 101.371% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1036.112% |
| IXICO plc | -4.44 Million USD | 151.582% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 82.657% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.82% |
| CSL Limited | 10.52 Billion USD | 99.978% |
| Cellectis S.A. | -43.81 Million USD | 105.232% |